Polatuzumab Vedotin-Piiq

Sold as Polivy. Every branded application for this active ingredient.

First approved: Jun 10, 2019
Branded applications: 1
New uses approved: 1
Complete response letters: 0

Applications

NDAs and BLAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Jun 10, 2019	PolivyBLA 761121 · New molecular entity	Genentech	3	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA